Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics Inc (NQ: KRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
8 Analysts Have This to Say About Karuna Therapeutics
  Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: 
Via Benzinga
Karuna Therapeutics: Q2 Earnings Insights
  Karuna Therapeutics (NASDAQ:KRTX) reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
SVB Likes This 'Novel Antipsychotic'-Focused Stock
Via Benzinga
JMP Views Positive Phase 3 Data Equivalent To 'Schizophrenia Blockbuster' For This Stock
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
GameStop, Signify Health And Some Other Big Gainers From Monday
U.S. stocks closed mixed on Monday. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Analyst Ratings for Karuna Therapeutics
Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: 
Via Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
From Karuna Therapeutics, Inc.
Via Business Wire
Nasdaq Turns Lower; Crude Oil Rises Over 1%
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Karuna Therapeutics (NASDAQ: KRTX) Reports Positive Primary and Secondary Endpoint Results from Phase 3 EMERGENT-2 Clinical Trial of KarXT for Treating Schizophrenia
Karuna Therapeutics, Inc. (NASDAQ: KRTX) is engaged as a clinical-stage biopharmaceutical company that is focused on the research and development 
Via Spotlight Growth
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6... 
Via Benzinga
Dow Jumps Over 150 Points; Karuna Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday. 
Via Benzinga
Karuna Therapeutics (KRTX) Stock Soars 64% on Positive Clinical Data
Karuna Therapeutics (KRTX) stock is rocketing higher on Monday thanks to results from a Phase 3 EMERGENT-2 trial to treat schizophrenia. 
Via InvestorPlace
Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win
Karuna Therapeutics easily beat expectations for its midstage test in schizophrenia. 
Via Investor's Business Daily
Why U.S. Stocks Are Trading Higher; Tyson Foods Earnings Miss Views
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday. 
Via Benzinga
Karuna Therapeutics Shares Surge After Encouraging Data From Schizophrenia Candidate
Karuna Therapeutics Inc (NASDAQ: KRTX) has  
Via Benzinga
Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness
Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.